Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
NLS Pharmaceutics ( (NLSP) ) just unveiled an update.
On November 4, 2024, NLS Pharmaceutics Ltd. entered into a merger agreement with Kadimastem Ltd., making Kadimastem a wholly owned subsidiary. As part of the merger process, NLS Pharmaceutics proposed several corporate actions, including a 1-for-10 reverse share split and a name change to NewcelX Ltd., which were approved in a meeting on September 29, 2025. These changes are set to be effective on October 30, 2025, and are expected to align with Nasdaq listing requirements, potentially impacting the company’s market positioning and shareholder structure.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a company involved in the research and development of pharmaceutical, chemical, medical-technical, biotechnological, and related products. The company focuses on acquiring, holding, and granting licenses and intellectual property rights, and providing services related to these fields.
Average Trading Volume: 676,799
Technical Sentiment Signal: Sell
Current Market Cap: $4.46M
For an in-depth examination of NLSP stock, go to TipRanks’ Overview page.